FocalTherics (NASDAQ:FOCL) Director Purchases $237,500.00 in Stock

Key Points

• Director Lance Willsey bought 50,000 shares of FocalTherics at $4.75 each, investing $237,500 and increasing his direct ownership by 4.03% to 1,291,780 shares.
• FocalTherics reported a quarterly loss of $0.39 per share, missing estimates by $0.19, while generating $13.2 million in revenue; analysts expect a full-year loss of $0.78 per share.
• Analyst sentiment is mixed, with the stock carrying a consensus “Hold” rating and a $7.75 target price. Institutional investors own 62.74% of the company’s shares.

FocalTherics (NASDAQ:FOCL - Get Free Report) Director Lance Willsey purchased 50,000 shares of FocalTherics stock in a transaction dated Friday, August 14th. The shares were bought at an average cost of $4.75 per share, for a total transaction of $237,500.00. Following the transaction, the director directly owned 1,291,780 shares of the company's stock, valued at approximately $6,135,955. The trade was a 4.03% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

FocalTherics Price Performance

Shares of FocalTherics stock opened at $4.76 on Monday. The company has a 50-day moving average price of $5.39. FocalTherics has a fifty-two week low of $1.30 and a fifty-two week high of $6.40. The company has a market capitalization of $178.40 million, a price-to-earnings ratio of -4.62 and a beta of -0.04. The company has a debt-to-equity ratio of 1.79, a quick ratio of 0.99 and a current ratio of 1.34.

FocalTherics (NASDAQ:FOCL - Get Free Report) last released its earnings results on Friday, August 14th. The company reported ($0.39) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.19). FocalTherics had a negative return on equity of 175.45% and a negative net margin of 56.26%.The firm had revenue of $13.20 million for the quarter. As a group, equities research analysts anticipate that FocalTherics will post -0.78 earnings per share for the current year.

Hedge Funds Weigh In On FocalTherics

Several institutional investors have recently modified their holdings of FOCL. Rock Springs Capital Management LP increased its holdings in shares of FocalTherics by 7.1% in the 1st quarter. Rock Springs Capital Management LP now owns 1,378,000 shares of the company's stock worth $5,126,000 after acquiring an additional 91,500 shares during the period. Flax Pond Capital LLC acquired a new position in FocalTherics during the 4th quarter valued at about $2,623,000. Leonteq Securities AG bought a new position in FocalTherics in the 4th quarter worth about $313,000. Kovack Advisors Inc. bought a new position in FocalTherics in the 4th quarter worth about $53,000. Finally, Lido Advisors LLC acquired a new stake in shares of FocalTherics in the first quarter valued at approximately $40,000. Institutional investors own 62.74% of the company's stock.

Analyst Ratings Changes

Several analysts have weighed in on the stock. Piper Sandler reiterated a "neutral" rating and set a $4.00 target price on shares of FocalTherics in a research note on Friday. Wall Street Zen lowered shares of FocalTherics from a "hold" rating to a "sell" rating in a report on Saturday. HC Wainwright reaffirmed a "buy" rating and set a $10.00 price objective on shares of FocalTherics in a research report on Tuesday, June 2nd. Finally, Mizuho set a $15.00 price objective on shares of FocalTherics and gave the stock an "outperform" rating in a research note on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $7.75.

FocalTherics Company Profile

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source